Navigation Links
Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
Date:11/26/2012

d gL antigens also contained HLAs that have previously been reported to contribute to the suppression of viremia and amelioration of disease. In summary, the elicitation, identification, and characterization of extensive T cell responses driven by Inovio's CMV SynCon constructs will provide an important tool for guiding clinical development of a CMV vaccine. Further ongoing work will determine how many of the 10 antigens will be selected and taken further for clinical development as well as assess the induction of antibody responses to prevent CMV infection.

About Cytomegalovirus
Cytomegalovirus (CMV) is a member of the herpes family of viruses that spreads from one person to another through the transfer of body fluids. CMV causes a wide variety of infection and illness in healthy adults, in those with compromised immune systems (such as HIV patients), and in pregnant women who can pass the infection to their unborn child (congenital CMV). It is the most common viral infection in solid organ transplant recipients and is considered a causative factor in certain cancers, inflammatory diseases, and cardiovascular/pulmonary diseases. CMV infects over 95% of people in some developing countries. In the US, 50 – 80% of people become infected with CMV by the time they are 40 years old. CMV is the most common viral infection that infants are born with in the United States. The US Institute of Medicine and US National Vaccine Program offices have ranked CMV with the highest priority in terms of potential healthcare dollar savings and improvement in "quality adjusted life years." Although healthy people usually have few symptoms at the time of initial infection, after infection the virus remains in a latent state in the body for the rest of a person's life. The virus can then be transmitted and cause infection through organ donation, or latent virus can become reactivated and cause symptomatic disease.

About Inovio Pharmaceuticals, Inc.
Inovio is
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
2. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
8. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... The Oklahoma tornado left the ... the mayor of Moore, one of the heavily damaged towns, ... report from cnn.com. Reaching out to also be of help, ... Safe Shield to counter the looming mold problem. , The ... 22, 2013, caused 24 deaths, My Cleaning Products shared. Ten ...
(Date:5/23/2013)... ROCK, Colo. , May 23, 2013 ... diagnostic company focused on obtaining FDA clearance and ... , today announced the pricing of an underwritten public ... related warrants to purchase 3,500,000 shares of its common ... at a combined public offering price of $1.25 per ...
(Date:5/23/2013)... , May 23, 2013 PuraMed BioScience ... and marketer of over-the-counter (OTC) medicinal and healthcare ... opinion on the company based on low market ... , Non-Prescription, All Natural Product to Treat Migraine ... Outperforms #1 Prescription Competitor , Currently Available ...
(Date:5/23/2013)... Calif. , May 23, 2013  Saddleback Memorial ... recently became the first hospital on the West ... technology. This new surgical option provides women with a ... Marc Winter , M.D., a ... and surgeon and medical director of minimally invasive surgery ...
Breaking Biology Technology:Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3
... Nile Therapeutics, Inc. (Nasdaq: NLTX ), a ... heart failure patients, today announced that, pursuant to Nasdaq ... fiscal year ended December 31, 2008, included in the ... 12, 2009, contained a going concern qualification from its ...
... Inc. (OTC Bulletin Board: TBIO) today announced financial results for ... Company,s financial results are presented in the tables that follow. ... loss of $219,000 or $0.00 per share for the fourth ... $212,000 or $0.00 per share for the fourth quarter of ...
... Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a ... drugs for the treatment of human viral diseases, today ... antiviral discovery and development programs have been accepted for ... Association for the Study of the Liver (EASL, April ...
Cached Biology Technology:Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives 2Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives 3Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 2Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 3Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 4Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 5Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 6Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 7Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results 8Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) 2Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) 3
(Date:5/22/2013)... in cellular DNA can endanger the whole organism, as ... at Ludwig-Maximilians-Universitaet (LMU) in Munich now report how byproducts ... helix. , The DNA in our cells controls the ... bodies. The instructions for this are encoded in the ... the bases adenine (A), cytosine (C), guanine (G) and ...
(Date:5/22/2013)... Calif., May 22, 2013 Early screening for prostate ... pregnancy testing is for women, thanks to UC Irvine ... American Chemical Society . , After more than a ... way to clearly identify clinically usable markers for prostate ... detected far sooner, with greater accuracy and at dramatically ...
(Date:5/21/2013)... NC Biologists have known for a long time ... why isn,t well understood, particularly for plants. But it ... Lanfear of Australian National University and the U. S. ... to be published 21 May in the journal ... plants have faster-changing genomes. , Drawing from a database ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3Small but speedy: Short plants live in the evolutionary fast lane 2
... , NEW YORK (February 24, 2012) A new ... Society, and others uses a new scientific methodology for ... "diversified portfolio" of management options from strict no-take ... methodology looks at existing information on the country,s climate, ...
... pm ET) Researchers have combined bioactive peptides to successfully ... published today in PLoS ONE , demonstrates that the ... and promotes re-growth of tissue. Further development of these peptides ... wounds. The team tested a newly-created peptide, UN3, ...
... from Karolinska Institutet in Sweden shows that a new ... ACR16 might operate via previously unknown mechanisms of ... ACR16 binds to the sigma-1 receptor, a protein in ... new knowledge can be used to develop future treatments ...
Cached Biology News:Study IDs new marine protected areas in Madagascar 2Novel bioactive peptides promote wound healing in vivo 2Novel bioactive peptides promote wound healing in vivo 3New knowledge on the pharmacology of dopamine stabilizers 2
... The Cetac Ultrasonic Nebulizers are available in two ... difference between these two models is that the ... to create a drier aerosol for improved detection ... detection limits for a range of elements by ...
...
... using a protein engineering approach that introduced amino ... wild-type DNase I. These changes markedly increase the ... is a versatile enzyme that has a 6-fold ... maintain at least 50% of peak activity in ...
... iTaq DNA polymerase is ... suitable for both conventional and ... is supplied at a concentration ... and includes 250 units polymerase, ...
Biology Products: